Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Part of paid clinical trials in Fayetteville, Arkansas.
- Sponsor
- Celgene
- Study ID
- NCT02285062
- Phase
- PHASE3
- Status
- Completed
Conditions
- Lymphoma, Large B-Cell, Diffuse
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- lenalidomide — DRUG
- Placebo — DRUG
- Rituximab — DRUG
- Cyclophosphamide — DRUG
- Doxorubicin — DRUG
- prednisone — DRUG
- vincristine — DRUG
Study Details
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
Key Dates
- Start date
- Feb 17, 2015
- Status verified
- May 2023
- Primary completion
- Mar 15, 2019
- Completion
- Jul 28, 2022
Study Design
- Enrollment
- 570 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: R2-CHOPLenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
- Active Comparator: R-CHOPPlacebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Primary Outcome Measure
Kaplan-Meier Estimate of Progression Free Survival (PFS) [ Time Frame: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months ]
Locations (22)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 177 | Fayetteville | Arkansas | 72703 | - |
| Local Institution - 136 | Orange | California | 92868 | - |
| Local Institution - 127 | Sacramento | California | 95817 | - |
| Local Institution - 169 | New Haven | Connecticut | 06510 | - |
| Local Institution - 128 | Hollywood | Florida | 33021 | - |
| McFarland Clinic | Ames | Iowa | 50010-3014 | - |
| Siouxland Hematology-Oncology Associates, LLP | Sioux City | Iowa | 51101-1733 | - |
| Local Institution - 143 | Fairway | Kansas | 66205 | - |
| Local Institution - 158 | Shreveport | Louisiana | 71103 | - |
| Center For Cancer And Blood Disorders | Bethesda | Maryland | 20817 | - |
| Local Institution - 101 | Minneapolis | Minnesota | 55416 | - |
| Local Institution - 138 | Minneapolis | Minnesota | 55455 | - |
| Local Institution - 112 | Rochester | Minnesota | 55905 | - |
| Local Institution - 103 | Durham | North Carolina | 27710 | - |
| Local Institution - 161 | Philadelphia | Pennsylvania | 19111 | - |
| Local Institution - 151 | Dallas | Texas | 75390-9068 | - |
| Local Institution - 951 | Dallas | Texas | 75235 | - |
| Local Institution - 146 | Salt Lake City | Utah | 84106 | - |
| Local Institution - 905 | Edmonds | Washington | 98026 | - |
| Local Institution - 903 | Issaquah | Washington | 98029 | - |
| Local Institution - 162 | Seattle | Washington | 98104 | - |
| Local Institution - 904 | Seattle | Washington | 98107 | - |
Find similar trials in Fayetteville, AR
Related Studies
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaPHASE1/PHASE2 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaPHASE2 · Recruiting · Jennifer Crombie, MD · Miami, Florida
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Mobile, Alabama
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )PHASE1 · Not Yet Recruiting · Eli Lilly and Company · Duarte, California